MedPath

Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)

The Safety of Non-vitamin K Oral Anticoagulants Compared to Warfarin Early After Cardiac Surgery

Phase 2
Active, not recruiting
Conditions
Atrial Fibrillation
Interventions
Drug: Non-vitamin K oral anticoagulants (NOACs)
First Posted Date
2021-08-16
Last Posted Date
2024-04-17
Lead Sponsor
St. Paul's Hospital, Canada
Target Recruit Count
100
Registration Number
NCT05006287
Locations
🇨🇦

St. Paul's Hospital, Vancouver, British Columbia, Canada

Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics

Phase 1
Completed
Conditions
Pulmonary Arterial Hypertension
Interventions
First Posted Date
2021-08-06
Last Posted Date
2021-08-06
Lead Sponsor
Bial - Portela C S.A.
Target Recruit Count
26
Registration Number
NCT04994119
Locations
🇩🇪

PAREXEL International - Early Phase Clinical Unit - Berlin, Berlin, Germany

ALT-801 DDI Study in Healthy Volunteers

First Posted Date
2021-07-22
Last Posted Date
2022-12-08
Lead Sponsor
Altimmune, Inc.
Target Recruit Count
40
Registration Number
NCT04972396
Locations
🇦🇺

Q-Pharm, Herston, Queensland, Australia

🇦🇺

CMAX Clinical Research, Adelaide, South Australia, Australia

Rivaroxaban in Left Ventricular Thrombus

Phase 4
Completed
Conditions
Left Ventricular Thrombus
Acute Coronary Syndrome
Interventions
First Posted Date
2021-07-21
Last Posted Date
2024-11-15
Lead Sponsor
National Institute of Cardiovascular Diseases, Pakistan
Target Recruit Count
261
Registration Number
NCT04970576
Locations
🇵🇰

National Institute of Cardiovascular Diseases, Karachi, Sindh, Pakistan

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

First Posted Date
2021-05-14
Last Posted Date
2024-05-08
Lead Sponsor
Mirati Therapeutics Inc.
Target Recruit Count
40
Registration Number
NCT04887194
Locations
🇺🇸

Goshen Health, Goshen, Indiana, United States

🇺🇸

MultiCare Health System, Tacoma, Washington, United States

🇺🇸

NEXT Oncology, Fairfax, Virginia, United States

Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data

Completed
Conditions
Pulmonary Embolism
Interventions
First Posted Date
2021-05-10
Last Posted Date
2023-07-28
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
98947
Registration Number
NCT04879407
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty

Conditions
Frailty
Stroke
Atrial Fibrillation
Anticoagulant-induced Bleeding
Interventions
First Posted Date
2021-05-07
Last Posted Date
2021-05-07
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
1000000
Registration Number
NCT04878497
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices

Phase 2
Completed
Conditions
Heart Failure
Interventions
Device: LVAD implant
First Posted Date
2021-04-29
Last Posted Date
2024-11-14
Lead Sponsor
Palak Shah
Target Recruit Count
30
Registration Number
NCT04865978
Locations
🇺🇸

Inova Fairfax Medical Campus, Falls Church, Virginia, United States

Early Versus Late Post Caesarean Section Oral Anticoagulation Initiation and Risk of Maternal Complications in Patients With Mechanical Heart Valve Prosthesis

First Posted Date
2021-04-22
Last Posted Date
2021-04-22
Lead Sponsor
Cairo University
Target Recruit Count
114
Registration Number
NCT04855110
Locations
🇪🇬

Faculty of medicine (Kasr Alainy), cairo university, Cairo, Egypt

Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data

Completed
Conditions
Kidney Failure, Chronic
Venous Thromboembolic Disease
Interventions
First Posted Date
2021-03-26
Last Posted Date
2021-07-26
Lead Sponsor
Johns Hopkins University
Target Recruit Count
14914
Registration Number
NCT04818151
Locations
🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath